Neoleukin Therapeutics (Neoleukin Therapeutics) EBIT : $-34.60 Mil (TTM As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Neoleukin Therapeutics EBIT?

Neoleukin Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $-5.57 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $-34.60 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Neoleukin Therapeutics's annualized ROC % for the quarter that ended in Sep. 2023 was -194.00%. Neoleukin Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -236.16%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Neoleukin Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 98.82%.

Neoleukin Therapeutics EBIT Historical Data

The historical data trend for Neoleukin Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neoleukin Therapeutics EBIT Chart

Neoleukin Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-31.58

-23.24

-41.55

-60.70

-59.10

Neoleukin Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT	Get a 7-Day Free Trial															-13.61	-14.25	-11.72	-3.07	-5.57

Competitive Comparison of Neoleukin Therapeutics's EBIT

For the Biotechnology subindustry, Neoleukin Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neoleukin Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neoleukin Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Neoleukin Therapeutics's EV-to-EBIT falls into.

Neoleukin Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.60 Mil.

Neoleukin Therapeutics (NAS:NLTX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Neoleukin Therapeutics's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-22.276 * ( 1 - 0% )	/	( (11.718	+	11.247)	/ 2 )
=	-22.276	/	11.4825
=	-194.00 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	94.005	-	3.387	-	( 82.062	-	max(0, 4.88	-	83.78	+	82.062	))
=	11.718

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	89.586	-	3.658	-	( 78.507	-	max(0, 5.212	-	79.893	+	78.507	))
=	11.247

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Neoleukin Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-22.276	/	( ( (9.696 + max(-1.669, 0))	+	(9.169 + max(-2.272, 0)) )	/	2 )
=	-22.276	/	( ( 9.696	+	9.169 )	/	2 )
=	-22.276	/	9.4325
=	-236.16 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.718)	-	(3.387	+	0	+	0)
=	-1.669

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.386)	-	(3.658	+	0	+	0)
=	-2.272

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Neoleukin Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	-34.603	/	-35.015
	=	98.82 %

Neoleukin Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Neoleukin Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Neoleukin Therapeutics (Neoleukin Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neoleukin Therapeutics Inc (NAS:NLTX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

188 East Blaine Street, Suite 450, Seattle, WA, USA, 98102

Website

https://www.neoleukin.com

Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.

Executives

Baker Bros. Advisors Lp	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Sean Michael Smith	officer: Principal Accounting Officer	C/O NEOLEUKIN THERAPEUTICS, INC., 188 E. BLAINE STREET, SUITE 450, SEATTLE WA 98102
Priti Patel	officer: Chief Medical Officer	C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE WA 98102
Erin Lavelle	director	C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Donna Cochener	officer: General Counsel, SVP Legal	C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, SUITE 450, SEATTLE WA 98102
Rohan Palekar	director	201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Jonathan G Drachman	director, officer: See Remarks	21823 30TH DRIVE SE, BOTHELL WA 98021
Carl Walkey	officer: Senior Vice President	C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Robert Ho	officer: Chief Financial Officer	360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Holly Vance	officer: General Counsel	C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE E., SEATTLE WA 98102
Martin Babler	director	C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Erin M. Lavelle	director	360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Jeremy Green	10 percent owner	45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Sarah B. Noonberg	director	331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080